In conclusion, there is an intensely felt need to expand the study of NLRP3 and other-than-NLRP3 inflammasomes’ role(s) in MS, using human neural cell-based experimental models to achieve a more detailed molecular picture and identify disease-modifying therapeutic targets. This evidence concerns the gene NLRP3 and myeloid sarcoma.